Drug Trial Radar · NCT05753501
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
135
Actual
Start
Jun 9, 2023
Primary completion
Mar 2031
Study completion Mar 2031
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed for the treatment of NHL. This study is a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101. Approximately 200 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide. Participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Conditions
- Hematologic Cancer
Interventions
ABBV-101Drug
Oral:Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)Time frame: Up to Approximately 88 Months
- Change in Laboratory ParametersTime frame: Up to Approximately 88 Months
- Change in Vital SignsTime frame: Up to Approximately 88 Months
- Change in Electrocardiogram (ECG)Time frame: Up to Approximately 88 Months
Locations
51 sites in 9 countries. Site status is shown where the registry gives one.
Arizona Oncology - Tucson - Wilmot Road /ID# 252351
Tucson, Arizona
UC Irvine Medical Center /ID# 263020
Orange, California
Stanford University - Palo Alto /ID# 249683
Palo Alto, California
Rocky Mountain Cancer Centers - Aurora /ID# 252237
Aurora, Colorado
Northwestern Medicine - Northwestern Memorial Hospital /ID# 249347
Chicago, Illinois
Beth Israel Deaconess Medical Center /ID# 249302
Boston, Massachusetts
Rutgers Cancer Institute of New Jersey /ID# 249323
New Brunswick, New Jersey
New York Oncology Hematology - Albany Cancer Center /ID# 252240
Albany, New York
Northwell Health - Monter Cancer Center /ID# 250422
Lake Success, New York
University of Rochester Medical Center /ID# 249324
Rochester, New York
University of Cincinnati /ID# 249299
Cincinnati, Ohio
Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309
Eugene, Oregon
University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 250341
Philadelphia, Pennsylvania
MD Anderson Cancer Center /ID# 249293
Houston, Texas
University Health Network_Princess Margaret Cancer Centre /ID# 253483
Toronto, Ontario, Canada
Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 253428
Montreal, Quebec, Canada
Hopital Saint-Louis /ID# 253663
Paris, France
Institut Bergonie /ID# 253664
Bordeaux, Gironde, France
CHU Montpellier - Hopital Saint Eloi /ID# 253666
Montpellier, Herault, France
CHRU Lille - Hopital Claude Huriez /ID# 253665
Lille, Nord, France
Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 256248
Nantes, Pays de la Loire Region, France
Institut Gustave Roussy /ID# 253662
Villejuif, Val-de-Marne, France
Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 257431
Berlin, Germany
Universitaetsklinikum Hamburg-Eppendorf /ID# 264566
Hamburg, Germany
Universitaetsklinikum Ulm /ID# 253742
Ulm, Baden-Wurttemberg, Germany
Universitaetsklinikum Wuerzburg /ID# 254636
Würzburg, Bavaria, Germany
Universitaetsmedizin Rostock /ID# 259657
Rostock, Mecklenburg-Vorpommern, Germany
Universitaetsklinikum des Saarlandes /ID# 257435
Homburg, Saarland, Germany
Yitzhak Shamir Medical Center /ID# 254566
Tsrifin, Central District, Israel
Hadassah Medical Center-Hebrew University /ID# 251123
Jerusalem, Jerusalem, Israel
The Chaim Sheba Medical Center /ID# 251122
Ramat Gan, Tel Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 259608
Tel Aviv, Tel Aviv, Israel
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII /ID# 260317
Bergamo, Italy
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255172
Bologna, Italy
IRCCS Ospedale San Raffaele /ID# 253531
Milan, Milano, Italy
ASST Grande Ospedale Metropolitano Niguarda /ID# 253532
Milan, Milano, Italy
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 253530
Turin, Piedmont, Italy
National Cancer Center Hospital East /ID# 250684
Kashiwa-shi, Chiba, Japan
Kyoto University Hospital /ID# 261837
Kyoto, Kyoto, Japan
National Cancer Center Hospital /ID# 250680
Chuo-ku, Tokyo, Japan
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.